Vyvanse® (lisdexamfetamine dimesylate) Positive Top-Line Results in Maintenance of Efficacy Study in Adults with Moderate to Severe Binge Eating Disorder
Lexington, Mass. – July 22, 2015 – For U.S. Audiences Only – Shire plc (LSE: SHP, NASDAQ: SHPG) today reported positive top-line results from a 39-week, long-term maintenance of efficacy study of Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) in adults with moderate to severe Binge Eating Disorder (B.E.D.).
The objective of the study was to evaluate the maintenance of efficacy between Vyvanse and placebo, based on the primary endpoint of time to relapse of binge eating symptoms in adults (aged 18 to 55) with moderate to severe B.E.D. During the 26-week, double-blind, randomized-withdrawal phase of the study, Vyvanse demonstrated superiority over placebo (p<0.001) on the primary efficacy endpoint of time to relapse. Additionally, at the conclusion of the study, the group continuing on Vyvanse had a significantly lower proportion of relapse (5/136, 3.7%) as compared to the placebo group (42/131, 32.1%).
Based on these results, as well as findings from a separate 12-month open-label safety extension study, the Company plans to submit a supplemental New Drug Application to the U.S. Food and Drug Administration by year end. The FDA will evaluate adding these data to the current labeling for Vyvanse.
“I am very encouraged by these new data because relapse of binge eating symptoms is an important and meaningful consideration for adults with moderate to severe binge eating disorder," said James I. Hudson, M.D., Sc.D., Professor of Psychiatry, Harvard Medical School, Director of the Biological Psychiatry Laboratory at McLean Hospital, Belmont, Mass., and principal investigator for the long-term maintenance of efficacy study, known as SPD489-346.
Vyvanse is approved in the U.S. for the treatment of moderate to severe B.E.D. in adults. Vyvanse is not for weight loss. It is not known if Vyvanse is safe and effective for the treatment of obesity.
Vyvanse is a federally controlled substance (CII) because it can be abused or lead to dependence. Keep Vyvanse in a safe place to prevent misuse and abuse. Selling or giving away Vyvanse may harm others, and is against the law.
In a separate, 12-month open-label safety extension study (SPD489-345) in adults with moderate to severe B.E.D., the safety profile for Vyvanse was generally consistent with that currently outlined in the United States Prescribing Information (USPI). During the 52-week open-label treatment phase, 17 patients treated with Vyvanse experienced serious adverse events (SAEs) and 54 patients on Vyvanse had treatment-emergent adverse events (TEAEs) that led to study discontinuation. The most commonly reported TEAEs in patients taking Vyvanse (reported in 5% or more of patients) included dry mouth, headache, insomnia, upper respiratory tract infection, nasopharyngitis, constipation, nausea, decreased appetite, irritability, bruxism, sinusitis, anxiety and feeling jittery.
“To our knowledge, Shire is the first to conduct a randomized-withdrawal study assessing pharmacotherapy in adults with moderate to severe B.E.D. This exemplifies our continued commitment to further understanding and addressing the needs of adults with this disorder,” said Philip J. Vickers, Ph.D., Head of Research and Development, Shire. “We look forward to working with the FDA as they evaluate the data.”
In 2013, the American Psychiatric Association (APA) recognized B.E.D., the most common eating disorder in US adults, as a distinct medical condition. The disorder occurs in both men and women, is seen across racial and ethnic groups, and can occur in normal weight, overweight and obese adults. Medication is not appropriate for all adults with B.E.D.
About The Studies
Study SPD489-346
This Phase 3, 39-week, multi-center, placebo-controlled, double-blind, dose-optimized, randomized-withdrawal design study evaluated the maintenance of efficacy between Vyvanse and placebo based on the primary endpoint of time to relapse of binge eating symptoms in adults with moderate to severe B.E.D. (N= 418) based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition – Text Revision (DSM-IV-TR®) criteria.
The study consisted of a 4-week screening period, a 12-week open-label treatment phase (4 weeks of dose optimization and 8 weeks of maintenance), followed by a 26-week, double-blind, randomized-withdrawal phase and a follow-up visit one week after the last on-treatment visit. During the dose-optimization period, all Vyvanse-treated patients were initiated at the 30-mg dose, and then titrated in 20-mg increments to their optimal dose (either 50-mg or 70-mg). Patients who met “response” criteria (one or fewer binge days each week for four consecutive weeks prior to the last visit at the end of the 12-week open-label phase and had a Clinical Global Impression-Severity [CGI-S] score of two or less at the same visit) were randomized to Vyvanse or placebo treatment groups. During this randomized-withdrawal phase, patients (N=275) received either ongoing treatment with the same optimized dose of Vyvanse from the open-label phase (N=137) or placebo (N=138).
The primary endpoint was defined as the time to relapse of binge eating symptoms during the randomized phase. Relapse was defined as a two or more point increase (worsening) in the investigator’s assessment of CGI-S score from the randomization baseline and two or more binge eating days per week in each week for two consecutive weeks prior to the visit. Vyvanse demonstrated superiority over placebo (p<0.001) on the primary efficacy endpoint of time to relapse. Additionally, at the conclusion of the study, the group continuing on Vyvanse had a significantly lower proportion of relapse of (5/136, 3.7%) as compared to the placebo group (42/131, 32.1%).
Safety and tolerability evaluations of Vyvanse included TEAEs and vital signs. The safety profile for Vyvanse in this study was generally consistent with the known profile reported in previous studies in adult patients with moderate to severe B.E.D.
During the 12-week open-label phase of the study, three patients treated with Vyvanse experienced SAEs and 22 patients on Vyvanse had TEAEs that led to study discontinuation. The most commonly reported TEAEs in patients taking Vyvanse (reported in 5% or more of patients) included dry mouth, headache, insomnia, decreased appetite, nausea, anxiety, constipation, hyperhidrosis, feeling jittery and diarrhea.
During the randomized-withdrawal phase, two patients treated with Vyvanse experienced SAEs and six patients on Vyvanse had TEAEs that led to study discontinuation. The most commonly reported TEAEs (reported in 5% or more of patients) in patients taking Vyvanse included nasopharyngitis, headache, upper respiratory tract infection and dry mouth, and in patients taking placebo included nasopharyngitis, headache, and fatigue. Further evaluation of the safety information is currently underway.
Study SPD489-345
This Phase 3, 53-week, multi-center, open-label extension, dose-optimized study was designed to assess the safety and tolerability of Vyvanse in adults with moderate to severe B.E.D. based on DSM-IV-TR® criteria (N= 604). Subjects enrolled were from previously completed double-blind, placebo-controlled studies.
The study consisted of a 4-week dose-optimization period, a 48-week maintenance period, and a follow-up visit 1 week after the last on-treatment visit.
Safety and tolerability evaluations included TEAEs, response to the Columbia-Suicide Severity Rating Scale (C-SSRS), vital signs, weight and waist circumference, clinical laboratory evaluations, and electrocardiogram (ECG) results.
During the 52-week open-label treatment phase, 17 patients treated with Vyvanse experienced SAEs and 54 patients on Vyvanse had TEAEs that led to study discontinuation. The most commonly reported TEAEs in patients taking Vyvanse (reported in 5% or more of patients) included dry mouth, headache, insomnia, upper respiratory tract infection, nasopharyngitis, constipation, nausea, decreased appetite, irritability, bruxism, sinusitis, anxiety and feeling jittery.
The safety profile for Vyvanse in this study was generally consistent with that currently outlined in the United States Prescribing Information (USPI).
Shire anticipates presenting the data from studies SPD489-346 and SPD489-345 at future scientific meetings.
About B.E.D.
Binge Eating Disorder (B.E.D.), recognized as a distinct disorder in 2013 by the APA, is defined as recurring episodes (on average, at least once weekly, for 3 months) of consuming a large amount of food in a short time, compared with what others would consume under the same or similar circumstances. Patients feel a sense of lack of control over eating during a binge eating episode and marked distress over their binge eating. They typically experience shame and guilt, among other symptoms, about their binge eating, and may conceal the symptoms. Unlike people with other eating disorders, adults with B.E.D. don’t routinely try to “undo” their excessive eating with extreme actions like purging or over-exercising. Adults with moderate to severe B.E.D. usually binge four to thirteen times per week. Only a doctor or other trained health care professional (HCP) can diagnose B.E.D. and determine an appropriate treatment plan.
B.E.D. is the most common eating disorder in U.S. adults and is more prevalent than anorexia and bulimia combined. The disorder occurs in both men and women, is seen across racial and ethnic groups, and can occur in normal weight, overweight, and obese adults. Medication is not appropriate for all adults with B.E.D.
ABOUT Vyvanse® (lisdexamfetamine dimesylate)
What is Vyvanse?
Vyvanse is a prescription medicine used for the treatment of moderate to severe Binge Eating Disorder (B.E.D.) in adults. Vyvanse is not for weight loss. It is not known if Vyvanse is safe and effective for the treatment of obesity.
IMPORTANT SAFETY INFORMATION
Vyvanse is a federally controlled substance (CII) because it can be abused or lead to dependence. Keep Vyvanse in a safe place to prevent misuse and abuse. Selling or giving away Vyvanse may harm others, and is against the law.
Vyvanse is a stimulant medicine. Tell the doctor if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs.
Who should not take Vyvanse?
Do not take Vyvanse if you are:
Problems that can occur while taking Vyvanse. Tell the doctor if you:
What are possible side effects of Vyvanse (lisdexamfetamine dimesylate)?
The most common side effects of Vyvanse reported in studies of adults with moderate to severe B.E.D. include:
|
|
|
|
|
|
For additional safety information, click here for Prescribing Information and Medication Guide and discuss with your doctor.
Vyvanse® is a registered trademark of Shire LLC. Vyvanse is available in 10, 20, 30, 40, 50, 60 and 70-mg capsules.
DSM-IV-TR® is a registered trademark of the American Psychiatric Association.
For further information please contact:
Investor Relations |
|
|
Sarah Elton-Farr |
+44 1256 894157 |
|
Media |
|
|
Scott Santiamo |
+1 484 343 2576 |
About Shire
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
THE “SAFE HARBOR” STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Statements included in this announcement that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, that: